Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Agne Paner, ASH 2019: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 18th 2019

At the 61st ASH Annual Meeting & Exposition, Agne Paner, Rush University Medical Center, discusses her presentation: Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias.

Questions

1. What are the major unmet needs in the treatment of relapsed/refractory multiple myeloma? (0:05)

2. What were the findings of the HORIZON study? (0:28)

3. What progress has been made in identifying biomarkers of response to Melflufen plus Dexamethasone in relapsed/refractory multiple myeloma? (1:37)

4. What combination therapies are being investigated for relapsed/refractory multiple myeloma? (1:53)

5. How does this treatment differ from other treatment options? (2:42)

 

Agne Paner has received consulting honoraria for advisory board from Oncopeptides.

Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup